Literature DB >> 11095818

Vaccination in Travelers.

.   

Abstract

Vaccination of populations throughout the world has led to dramatic decreases in morbidity and mortality from many infectious diseases, including poliomyelitis and measles. In the United States, for example, morbidity and mortality from invasive disease from Haemophilus influenzae type b has decreased more than 99%. International travelers should ensure that they are up-to-date on their routine immunizations and then consider vaccination against other diseases based on risk. This article reviews new vaccines such as those against rotavirus, Lyme disease, and enterotoxigenic Escherichia coli and provides updated information on the risk of typhoid fever and the efficacy of vaccination against it. The use of hepatitis A vaccine in outbreak control, the safety of yellow fever vaccine, and the importance of protecting travelers against rabies exposure are also discussed. Vaccination is an important way for travelers to maintain their health before, during, and after travel.

Entities:  

Year:  1999        PMID: 11095818     DOI: 10.1007/s11908-999-0053-z

Source DB:  PubMed          Journal:  Curr Infect Dis Rep        ISSN: 1523-3847            Impact factor:   3.725


  47 in total

1.  Recommendations of the Advisory Committee on Immunization Practices: revised recommendations for routine poliomyelitis vaccination.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-07-16       Impact factor: 17.586

2.  Anaphylaxis from yellow fever vaccine.

Authors:  J M Kelso; G T Mootrey; T F Tsai
Journal:  J Allergy Clin Immunol       Date:  1999-04       Impact factor: 10.793

3.  Impact of vaccines universally recommended for children--United States, 1990-1998.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-04-02       Impact factor: 17.586

4.  Cholera vaccination in refugee settings.

Authors:  R J Waldman
Journal:  JAMA       Date:  1998-02-18       Impact factor: 56.272

5.  Efficacy of hepatitis A vaccine in prevention of secondary hepatitis A infection: a randomised trial.

Authors:  L Sagliocca; P Amoroso; T Stroffolini; B Adamo; M E Tosti; G Lettieri; C Esposito; S Buonocore; P Pierri; A Mele
Journal:  Lancet       Date:  1999-04-03       Impact factor: 79.321

6.  Safety and immunogenicity of an oral, killed enterotoxigenic Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults.

Authors:  S J Savarino; F M Brown; E Hall; S Bassily; F Youssef; T Wierzba; L Peruski; N A El-Masry; M Safwat; M Rao; M Jertborn; A M Svennerholm; Y J Lee; J D Clemens
Journal:  J Infect Dis       Date:  1998-03       Impact factor: 5.226

7.  Short-term safety of live attenuated Japanese encephalitis vaccine (SA14-14-2): results of a randomized trial with 26,239 subjects.

Authors:  Z L Liu; S Hennessy; B L Strom; T F Tsai; C M Wan; S C Tang; C F Xiang; W B Bilker; X P Pan; Y J Yao; Z W Xu; S B Halstead
Journal:  J Infect Dis       Date:  1997-11       Impact factor: 5.226

Review 8.  Yellow fever: a decade of reemergence.

Authors:  S E Robertson; B P Hull; O Tomori; O Bele; J W LeDuc; K Esteves
Journal:  JAMA       Date:  1996-10-09       Impact factor: 56.272

9.  Cost-effectiveness of oral cholera vaccine in a stable refugee population at risk for epidemic cholera and in a population with endemic cholera.

Authors:  J Murray; D A McFarland; R J Waldman
Journal:  Bull World Health Organ       Date:  1998       Impact factor: 9.408

10.  A controlled trial of a formalin-inactivated hepatitis A vaccine in healthy children.

Authors:  A Werzberger; B Mensch; B Kuter; L Brown; J Lewis; R Sitrin; W Miller; D Shouval; B Wiens; G Calandra
Journal:  N Engl J Med       Date:  1992-08-13       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.